135 related articles for article (PubMed ID: 36819145)
1. Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.
Karmali R; St-Pierre F; Ma S; Foster KD; Kaplan J; Mi X; Pro B; Winter JN; Gordon LI
EJHaem; 2023 Feb; 4(1):108-114. PubMed ID: 36819145
[No Abstract] [Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Gordon LI; Karmali R; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau FI; Radford J; de Oteyza JP; Zinzani PL; Iyer SP; Townsend W; Miao H; Proscurshim I; Wang S; Katyayan S; Yuan Y; Zhu J; Stumpo K; Shou Y; Carpio C; Bosch F
Oncotarget; 2023 Jan; 14():57-70. PubMed ID: 36702329
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Gordon LI; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau I; Radford JA; Pérez de Oteyza J; Zinzani PL; Iyer S; Townsend W; Karmali R; Miao H; Proscurshim I; Wang S; Wu Y; Stumpo K; Shou Y; Carpio C; Bosch F
Clin Cancer Res; 2020 Jul; 26(14):3546-3556. PubMed ID: 32327472
[TBL] [Abstract][Full Text] [Related]
5. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
7. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
[TBL] [Abstract][Full Text] [Related]
8. A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW; Kaplan J; Levy M; Bixby D; Burke PW; Erba H; Wise-Draper TM; Roboz GJ; Papadantonakis N; Rajkhowa T; Hernandez D; Dobler I; Gregory RC; Li C; Wang S; Stumpo K; Kannan K; Miao H; Levis M
Haematologica; 2023 Mar; 108(3):705-716. PubMed ID: 36226495
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Zelenetz AD; Salles G; Mason KD; Casulo C; Le Gouill S; Sehn LH; Tilly H; Cartron G; Chamuleau MED; Goy A; Tam CS; Lugtenburg PJ; Petrich AM; Sinha A; Samineni D; Herter S; Ingalla E; Szafer-Glusman E; Klein C; Sampath D; Kornacker M; Mobasher M; Morschhauser F
Blood; 2019 May; 133(18):1964-1976. PubMed ID: 30850381
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
[TBL] [Abstract][Full Text] [Related]
13. Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Drott K; Hagberg H; Papworth K; Relander T; Jerkeman M
Blood Adv; 2018 Jun; 2(12):1386-1392. PubMed ID: 29903707
[TBL] [Abstract][Full Text] [Related]
14. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of durvalumab with R-CHOP or R
Nowakowski GS; Willenbacher W; Greil R; Larsen TS; Patel K; Jäger U; Manges RF; Trümper L; Everaus H; Kalakonda N; Brown P; Jørgensen JM; Cunningham D; Dell'Aringa J; Fox B; Rubio ND; Kilavuz N; Casadebaig ML; Manzke O; Munoz J
Int J Hematol; 2022 Feb; 115(2):222-232. PubMed ID: 34797531
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
17. Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.
Miura K; Takahashi H; Nakagawa M; Hamada T; Uchino Y; Iizuka K; Ohtake S; Iriyama N; Hatta Y; Nakamura H
Expert Rev Anticancer Ther; 2022 Jun; 22(6):583-595. PubMed ID: 35472312
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]